GEMME – Générique, même médicament, was created in 2002 when 9 of the main laboratories in France joined to create an association to represent the industry of genereic drugs in light of several factors:
– Numerous measures were being taken regarding the development of generic drugs without consulting the key players
– Generic drugs represented an emerging market within the pharma industry
Today it comprises 11 companies, encompassing almost all the key players in generics
Address: Une association loi 1901, 6 avenue Franklin D. Roosevelt, 75008 Paris, France
Tel: +33(0)140746430
Web: http://www.medicamentsgeneriques.info/
Catherine Bourrienne-Bautista, Déléguée générale of the GEMME (L’association Genérique Même Medicament, France’s generics and biosimilars association), provides her take on the state of the generics and biosimilars industry in France.…
The director of GEMME reveals how the French generics market is young in comparison to other European countries – where generics were on the market twenty years before they became…
Generic drugs were a very late arrival for the French market in comparison with other European markets and healthcare systems on a par with the French one. Today the gap…
Martine Claret of Horus Pharma – a family-owned ophthalmology pharmaceutical company established in 2003 and based in Nice – discusses the highly regulated and competitive ophthalmology market, the company’s remarkable…
Faten Hidri, VP for Higher Education & Research in the Paris Region (Ile de France), discusses the vital role of academic research and the life sciences in her region and…
Pascal Girin, CEO of BALT, shares how his rich career in neurovascular medical technology helped him to transform the company from a small R&D pure player into an international market…
Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to…
Bertrand Sohier, VP and general manager business and administration of Parexel France discusses the latest trends impacting the clinical research environment of the country, gives insight on the strategies the…
Michel Spagnol, chairman and CEO of Novasep, a robust French CDMO, shares his insights on the key global trends that are shaping today’s CMDO sector – particularly the emerging significance…
France is rediscovering its mojo. After a period of relative stagnation, the country’s highly strategic USD 65 billion healthcare and life sciences market is once again an attractive investment proposition.…
Jean-Marc Grognet, general manager of Genopole, France’s leading biotechnology cluster, explains the organization’s unique triangular structure with the corner points of the cluster being higher education, research, and industry. Grognet…
Jean-Louis Anspach, general manager of Teva France, elaborates on the affiliate’s transitional restructuring period as they make a turnaround effort in the face of group-wide challenges. Anspach goes on to…
Patrick Mahieux, general manager of ABL Europe, a CDMO specialized in the provision of viral vectors, discusses the company’s history within the Institut Mérieux and, the unique and flexible strategy…
Jaques Chevallet, CEO of Arkopharma, a European leader in herbal medicines and dietary supplements, discusses the company’s development over recent years while sharing his assessment on the current condition of…
Elizabeth Ducottet, the 5th generation CEO of French family company Thuasne, shares the group’s history and goes on to explain how it has evolved into a professionally and innovatively driven…
See our Cookie Privacy Policy Here
